SYDNEY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company) the Company developing a new class of synthetic anti-infectives, today announced it ...

Recce Pharmaceuticals’ synthetic gel successfully treated a range of skin infections in a phase 2 trial, leading the Australian biotech to point to the anti-infective's potential to counter ...

RECCE 327 developed by Recce Pharmaceuticals Ltd (ASX:RCE) has destroyed every bacterium it has been tested against, including superbugs, and has proved invulnerable to any attempt by bacteria to ...

For the best experience, please enable JavaScript in your browser settings. Part of Jomo Kenyatta International Airport grassland towards 75 Airport North Road on ...

A Phase II trial of Recce Pharmaceutical’s topical skin infection gel has ‘exceeded expectations’, with 93% of patients achieving the primary efficacy endpoint. The Australian company’s ...

Recce Pharmaceuticals has shared positive data from a mid-stage study of its RECCE 327 topical gel (R327G) in acute bacterial skin and skin structure infections (ABSSSIs). The open-label phase 2 trial ...

Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. A successful phase II clinical trial has taken place, assessing efficacy and safety of R327G in ...